Histamine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Histamine Receptors [75, 163] ) are activated by the endogenous ligand histamine. Marked species differences exist between histamine receptor orthologues [75] . The human and rat H 3 receptor genes are subject to significant splice variance [12]. The potency order of histamine at histamine receptor subtypes is H 3 = H 4 > H 2 > H 1 [163] . Some agonists at the human H 3 receptor display significant ligand bias [171] . Antagonists of all 4 histamine receptors have clinical uses: H 1 antagonists for allergies (e.g. cetirizine), H 2 antagonists for acid-reflux diseases (e.g. ranitidine), H 3 antagonists for narcolepsy (e.g. pitolisant/WAKIX; Registered) and H 4 antagonists for atopic dermatitis (e.g. ZPL-3893787; Phase IIa) [163] and vestibular neuritis (AUV) (SENS-111 (Seliforant, previously UR-63325), entered and completed vestibular neuritis (AUV) Phase IIa efficacy and safety trials, respectively) [205, 8] .

